148 related articles for article (PubMed ID: 19671684)
1. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells.
Yuvaraj S; Griffin AC; Sundaram K; Kirkwood KL; Norris JS; Reddy SV
Mol Cancer Res; 2009 Aug; 7(8):1399-407. PubMed ID: 19671684
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment.
Sambandam Y; Sundaram K; Liu A; Kirkwood KL; Ries WL; Reddy SV
Oncogene; 2013 Jan; 32(1):97-105. PubMed ID: 22330139
[TBL] [Abstract][Full Text] [Related]
3. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice.
Pandruvada SN; Yuvaraj S; Liu X; Sundaram K; Shanmugarajan S; Ries WL; Norris JS; London SD; Reddy SV
Int J Cancer; 2010 May; 126(10):2319-29. PubMed ID: 19816883
[TBL] [Abstract][Full Text] [Related]
4. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells.
Sambandam Y; Ethiraj P; Hathaway-Schrader JD; Novince CM; Panneerselvam E; Sundaram K; Reddy SV
J Cell Physiol; 2018 Aug; 233(8):6125-6134. PubMed ID: 29323724
[TBL] [Abstract][Full Text] [Related]
5. RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma.
Ethiraj P; Sambandam Y; Hathaway-Schrader JD; Haque A; Novince CM; Reddy SV
J Cell Physiol; 2020 Feb; 235(2):1663-1673. PubMed ID: 31309556
[TBL] [Abstract][Full Text] [Related]
6. 1α,25-dihydroxyvitamin D3 modulates CYP2R1 gene expression in human oral squamous cell carcinoma tumor cells.
Sundaram K; Sambandam Y; Tsuruga E; Wagner CL; Reddy SV
Horm Cancer; 2014 Apr; 5(2):90-7. PubMed ID: 24497297
[TBL] [Abstract][Full Text] [Related]
7. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
Biswas S; Sengupta S; Roy Chowdhury S; Jana S; Mandal G; Mandal PK; Saha N; Malhotra V; Gupta A; Kuprash DV; Bhattacharyya A
Breast Cancer Res Treat; 2014 Jan; 143(2):265-76. PubMed ID: 24337540
[TBL] [Abstract][Full Text] [Related]
8. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
9. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
[TBL] [Abstract][Full Text] [Related]
10. RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells.
Sambandam Y; Sakamuri S; Balasubramanian S; Haque A
J Cell Biochem; 2016 Jan; 117(1):118-25. PubMed ID: 26095774
[TBL] [Abstract][Full Text] [Related]
11. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.
Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL
Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL.
Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A
J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
14. STAT-6 mediates TRAIL induced RANK ligand expression in stromal/preosteoblast cells.
Sundaram K; Sambandam Y; Balasubramanian S; Pillai B; Voelkel-Johnson C; Ries WL; Reddy SV
Bone; 2015 Feb; 71():137-44. PubMed ID: 25445452
[TBL] [Abstract][Full Text] [Related]
15. DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.
Sundaram K; Mani SK; Kitatani K; Wu K; Pestell RG; Reddy SV
J Cell Biochem; 2008 Apr; 103(6):1747-59. PubMed ID: 17891780
[TBL] [Abstract][Full Text] [Related]
16. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma.
Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J
Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484
[TBL] [Abstract][Full Text] [Related]
18. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression.
Biswas S; Roy Chowdhury S; Mandal G; Purohit S; Gupta A; Bhattacharyya A
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):502-511. PubMed ID: 30553016
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
20. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
